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problems with cognitive functions and problems with emotional dysregulation. 
ADHD was seen to impact everyday activities, social interactions and emotional 
functioning. These impacts had implications for the achievements at school; 
self-esteem and indulgence in risky behavior. Variables that moderate these 
impacts were also identified. The interrelationships among variables will be 
presented. The model was used to inform a strategy to evaluate outcomes of 
pharmacological treatments in adolescents with ADHD. The plausibility of the 
model was confirmed based on discussions with clinicians and drug 
development experts. CONCLUSIONS: An ADHD disease conceptual model was 
developed based on information from literature and stakeholders interviews, to 
describe ADHD in adolescents. It will be used to develop a strategy for PRO 
development in adolescent ADHD and identify new outcomes.  
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OBJECTIVES: To compare socio-demographic characteristics, comorbidities, 
health care resource use and work productivity assessments among adults 
diagnosed with attention-deficit/hyperactivity disorder (ADHD) from Europe (E) 
and the United States (US). METHODS: Data are from the 2011 National Health 
and Wellness Survey (NHWS), conducted online annually by Kantar Health 
among samples of adults obtained from international consumer panels. Data 
reported in this study were gathered September-December 2011 in Germany, UK, 
France, Spain, Italy, and the U.S. Comparisons of ADHD and non-ADHD control 
populations were presented previously. Those results are extended below, by 
comparing to differences between European and U.S. study participants, using 
chi-square tests of proportions. RESULTS: A total of 235 European and 676 US 
NHWS participants reported having received a diagnosis for ADHD from a health 
care professional. Diagnosed ADHD respondents were more frequently male 
(59% E vs. 56% US) and less likely married (38% E vs. 33% US) than non-ADHD 
controls. ADHD respondents were more likely to report sleep difficulties (67% E 
vs. 44% US; p<.05), anxiety (61% E vs. 58% US), depression (59% E vs. 60% US), or 
headaches (57% E vs. 63% US) than non-ADHD controls. Likelihoods of an 
emergency room visit (34% E vs. 24% US; p<0.05), or a hospitalization (32% E vs. 
12% US; p<0.05) within the past 6 months were greater among diagnosed ADHD 
respondents than non-ADHD controls. Diagnosed ADHD respondents were also 
more likely to report health-related work productivity loss (55% E vs. 34% US; 
p<0.05). CONCLUSIONS: Adults from Europe and the US reported high rates of 
comorbidity with various mental, emotional, or physical disorders, high rates of 
health resource utilization, and high rates of health-related work productivity 
loss, with many of these higher among European than US participants.  
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OF LIFE (HRQOL) IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)  
Florea I1, Danchenko N2, Loft H1, Rive B3, Pendlebury S4, Abetz L5 
1H. Lundbeck A/S, Valby, Denmark, 2Lundbeck SAS, Issy-les-Moulineaux , France, 3Lundbeck 
S.A.S., Issy-Les Moulineaux, France, 4Mediplex Ltd, Leeds, UK, 5Adelphi Values, Bollington, 
Cheshire, UK  
OBJECTIVES: Depression has a significant detrimental effect on HRQoL and 
functioning. The aim of this study was to assess HRQoL outcomes in randomized 
placebo-controlled studies of adult MDD patients receiving vortioxetine. 
METHODS: Effects on HRQoL and functioning were evaluated in adult MDD 
patients using the Short-Form 36 (SF-36), the Quality of Life Enjoyment and 
Satisfaction Scale-Short Form (Q-LES-Q-SF), the EuroQoL Five-Dimension (EQ-
5D), the Health Status Questionnaire (HSQ-12) and the Sheehan Disability Scale 
(SDS). Furthermore, HRQoL and functioning were assessed in a short-term study 
in elderly MDD patients (≥65 years). A random effects meta-analysis was 
performed on the short-term vortioxetine studies (n=4 for SF-36 and n=7 for 
SDS). Values are presented as change from baseline versus placebo. RESULTS: 
Adult patients were treated with placebo (n=1316) or vortioxetine (n=2155). The 
meta-analysis (FAS, MMRM) showed a statistically significant difference to 
placebo in favour of vortioxetine in the SF-36 Mental Component Summary 
(MCS) score (5mg: 2.6, p=0.001, n=604; 20mg: 4.8, p<0.001, n=328) and 4 domain 
scores (vitality, social functioning, role-emotional, and mental health). 
Standardised effect sizes showed the clinical relevance of these results. 
Improvement was significantly different from placebo in the EQ-5D Health State 
score for vortioxetine 10mg (7.5 points, p<0.05, n=86) (FAS, MMRM) and the Q-
LES-Q total score for vortioxetine 15mg (3.3 points, p<0.01, n=127) and 20mg (4.5 
points, p<0.0001, n=134) (FAS, LOCF). Improvement in functioning, measured 
with the SDS, was in favour of vortioxetine 10mg (-1.7, p=0.004, n=269) and 20mg 
(-2.4, p=0.006, n=234) (FAS, MMRM). In the elderly study, improvement in the 
HSQ-12 for vortioxetine 5mg (n=136) was significantly different from placebo 
(n=128) for Health Perception (10.4, p<0.0001), Mental Health (7.9, p<0.001), and 
Energy (6.4, p<0.05) domains (FAS, MMRM). CONCLUSIONS: Vortioxetine showed 
significant and meaningful improvements in HRQoL and functioning versus 
placebo across several MDD trials and relevant outcome instruments.  
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OBJECTIVES: This research presents an approximating model of global 
treatment satisfaction (GS) created using econometric techniques. GS questions 
are usually worded, “All things considered, how satisfied are you with the care 
you received…?” The economic interpretation of GS is higher satisfaction 
corresponds to higher utility. When thought of as utility, GS is tied to the 
assumptions of utility maximizing imbedded in consumer theory, and more 
specifically, to the concept of demand. Attempts in the literature to measure GS 
fall short because of lack of theoretical guidance and inconsistency in 
measurement and variable operationalization. We avoid these limitations by 
presenting a methodological approach that makes it possible to view GS from an 
economic perspective. METHODS: The model is based on data from an outcomes 
study of substance abuse treatment services; however, it can be used for any 
treatment population. The participants are 311 adults (average age 36.4) 
discharged from primary treatment (ASAM Level 1A) in 2006-2010. The model is 
based on a single ordinal five-item GS variable and two treatment-relevant 
covariates: post-treatment time abstinent from use (treatment outcome), and an 
adjustor variable indicating addiction severity. GS is treated as a latent variable. 
It is specified using ordered probit regression under the log-linear functional 
form. The structural part of the relation is isolated by setting the model error 
term to zero. RESULTS: The model estimate for the outcome variable is 0.205 
(S.E. 0.041; X2<0.0001), and for the severity variable 0.722 (S.E. 0.431; χ2 N.S). A set 
of GS indifference curves are presented based on severity and outcome 
equivalencies. CONCLUSIONS: The effort necessary to obtain higher GS 
increases on the margin. This is important given the strong relationship between 
addiction severity and treatment cost and given treatment resource constraints. 
This technique can be incorporated into the quality assurance activities in any 
health care setting.  
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OBJECTIVES: Prescribing of more than one antidepressant drug (poly-pharmacy) 
is not clinically substantiated in literature and such a practice could contribute 
to additional side-effects. Antidepressant drugs are prescribed to patients 
diagnosed with psychiatric and non-psychiatric medical conditions. The 
objective of this study was to determine the patient demographics, non-
demographic factors and physician characteristics associated with prescribing 
poly-pharmacy antidepressants in both psychiatric and non-psychiatric cases. 
METHODS: The 2000-2009 National Ambulatory Medical Care Survey database 
was accessed for medical records of patients who were prescribed the 
antidepressant drugs. The medical records were sorted into psychiatric and non-
psychiatric categories. A logistic regression analysis helped determine the 
patient demographic, non-demographic and physician characteristics associated 
with prescribing poly-pharmacy antidepressant drugs. RESULTS: For patients 
diagnosed with psychiatric illnesses: Patient demographic factors of age 
(p<0.0001), gender (p=0.0087), race/ethnicity (p=0.0091), method of payment 
(p=0.0283), non-demographic factors of diagnosis (p<0.0001), and number of 
medical condition diagnosed (p<0.0001, OR=1.259, CI=1.125-1.408) were 
significantly associated with prescribing poly-pharmacy antidepressant drugs. 
Among the physician related factors, physician specialty (p<0.0001) and the 
region of practice (South) (p=0.0475) were significantly associated with 
prescribing poly-pharmacy antidepressant drugs. For patients diagnosed with 
non-psychiatric illnesses: Patients’ age (p<0.0001), method of payment 
(p=0.0444), and among the non-demographic characteristics, the number of 
medical conditions diagnosed (p=0.0246, OR=1.16, CI=1.019-1.320), and patients 
diagnosed with circulatory system disease (p=0.0111) were significantly 
associated with the practice of poly-pharmacy. Of the physician related factors 
physicians classified as owners of non-solo practice (p=0.0306) were significantly 
associated with prescribing poly-pharmacy antidepressant drugs. 
CONCLUSIONS: The fact that more than 40% of poly-pharmacy antidepressant 
drugs was prescribed to patients diagnosed with non-psychiatric illnesses, and 
the significant association between the poly-pharmacy antidepressants 
prescribed and the number of medical conditions diagnosed in both psychiatric 
and non-psychiatric patients lends to further investigation as to the 
reasonableness of such practices.  
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Gadelha CA 
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OBJECTIVES: Several medicines are available in the Brazilian public health 
system (SUS) to treat schizophrenia. The Ministry of Health (MoH) and Brazilian 
states share the responsibility of acquiring the atypical antipsychotics, which 
have significant impact on the public budget. Here, we present the profile of 
financial resources allocated in the acquisition of atypical antipsychotics in the 
SUS. METHODS: Descriptive analysis of expenses with drugs, based on the 
amount dispensed and acquisition prices in 2011. Data were obtained from MoH 
databases. For quetiapine, olanzapine, risperidone and ziprasidone, we assumed 
the financial resources applied by both states and MoH; for clozapine, we needed 
to accounted only the MoH resources (current values of 2011; exchange rate: 
US$1 = R$2.04). RESULTS: In 2011, expenses with atypical antipsychotics 
(clozapine, quetiapine, olanzapine, risperidone, and ziprasidone) for 
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schizophrenia in Brazil reached to US$195,885,270.68. Of this amount, only US$ 
R$7,496,366.58 (3.83%) came from states and US$188,388,904.10 (96.17%) from 
MoH resources. This value represented 11% of MoH’s annual budget for 
acquisition of high-cost medicines. Olanzapine and quetiapine accounted for 
nearly 81% of total expenses with atypical antipsychotics (US$103,763,938.18 and 
US$55,419,573.97, respectively). The others agents represented lower impacts: 
US$23,199,945.99 (ziprasidone), US$12,881,256.10 (clozapine) and US$620,556.45 
(risperidone). CONCLUSIONS: The data demonstrate the impact of financial 
resources applied in atypical antipsychotics to treat schizophrenia in SUS. In this 
scenario, strategies to strengthen the health industrial complex and to optimize 
resource allocation, as the current production of olanzapine and quetiapine in 
public pharmaceutical laboratories, are very desirable.  
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OBJECTIVES: Prescription drug monitoring programs (PDMPs) can help 
pharmacists provide appropriate care to patients taking controlled prescription 
drugs (CPDs). Study objectives were to 1) describe pharmacists’ views on 
mandating PDMP use and providing opioid addiction counseling; 2) determine 
what demographic and practice characteristics are associated with CPD-related 
continuing education (CE) hours; and 3) describe actions associated with 
dispensing CPDs. METHODS: This cross-sectional mail survey of 998 randomly 
selected Texas community pharmacists was part of a larger study to examine 
pharmacists’ intention to utilize a PDMP. Data were collected anonymously from 
2/12-4/12. Descriptive and inferential statistics were used to address the study 
objectives. RESULTS: The useable response rate was 26.2%. Pharmacists were 
more supportive of mandating PDMP use for physicians (4.1±1.2) than for 
pharmacists (3.2±1.5), (1=strongly disagree to 5=strongly agree). Male, BS degreed, 
pharmacy owners (vs. managers) and ≥50 year old pharmacists reported 
significantly (p<0.05) more CE hours related to prescription opioid abuse and 
pain management. CE was significantly correlated with pharmacists’ agreement 
to provide counseling (p=0.02). More than 45% of pharmacists were “always” 
prompted to use the PDMP when: patients paid cash (48.1%), prescription had 
mistakes (68.1%) and early refill request were made (66.3%). Prior to dispensing 
CPDs, more than 45% of pharmacists “always” consulted patient records (49.2%), 
verified prescribers DEA (48.0%) and patient identification (47.5%). Almost 40% of 
pharmacists “never” discussed buprenorphine/naloxone with patients or 
prescribers if they suspected abuse; instead 92.3% refused to fill the prescription 
and 44.0% were neutral regarding notifying law enforcement and counseling 
(35.1%). Pharmacists with a BS degree expressed higher agreement with opioid 
addiction counseling (p=0.02). CONCLUSIONS: Older male pharmacists received 
more CE and seemed more willing to provide counseling to patients with opioid 
addiction. As PDMP use becomes more prevalent, pharmacists should be 
prepared to interact and counsel patients with addictive patterns of prescription 
opioid use.  
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OBJECTIVES: Quantify changes in health care resource utilization and costs 
following clozapine initiation in Medicaid beneficiaries with schizophrenia or 
schizoaffective disorders. METHODS: Data were derived from the MarketScan 
Medicaid database for dates of service between 2007-2009. Patients had >1 
clozapine claim without clozapine use in the 12 months prior to the initiation 
(index) date; had >1 diagnosis of schizophrenic disorder (ICD-9-CM=295.xx) in the 
12 months prior (preperiod) through 12 months after (postperiod) index; were 
continuously enrolled throughout the preperiod and postperiod; and were aged 
18-64 years. Outcome measures included health care payments and resource 
utilization in 3 categories: all-cause (primary outcome); disease-specific (mental 
health and schizophrenia diagnoses); and cardiometabolic (cardiovascular or 
diabetes diagnoses). Comparisons of preperiod versus postperiod values were 
made using paired t-tests and McNemer’s tests for continuous and categorical 
variables, respectively. RESULTS: Mean patient age (n=1,045) was 36.32 years; 
56.1% male. Following clozapine initiation, mean 12-month all-cause health care 
payments did not change significantly (preperiod=$27,407, postperiod=$26,518, 
P=0.415). Payments for mental health and schizophrenia-related claims declined 
by 13.6% (P<0.001) and 11.7% (P=0.016), respectively. Increases in outpatient costs 
were offset by inpatient service cost reductions; significant declines were 
observed from the preperiod to the postperiod in the percentages of patients 
with hospitalizations for all causes (40.6% vs. 35.7%, P=0.003), mental disorders 
(40.2% vs. 35.1%, P<0.001), and schizophrenia (35.9% vs. 31.6%, P=0.007). No 
significant changes in cardiovascular or diabetes costs were observed. 
CONCLUSIONS: Clozapine initiation was associated with reductions in disease-
specific health care utilization and costs without increased cardiometabolic 
costs.  
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OBJECTIVES: To identify sociodemographic factors associated with off-patent 
brand antidepressants utilization. METHODS: Secondary data analysis was 
conducted using 2010 Medical Expenditure Panel Survey (MEPS). Although the 
following medications were available in generic products as of 2010: Venlafaxine, 
Fluoxetine, Paroxetine, Bupropion, Citalopram, Sertraline, Mirtazapine. 216 
unique participants were identified as brand users out of 1694 participants 
taking the aforementioned medications. Race, family’s total income, health 
insurance coverage, gender, and age were categorized and included first in 
bivariate logistic regression to identify significant predictor variables for the 
utilization of off-patent brand antidepressants. Charlson Co-morbidity Index 
(CCI) score was calculated using ICD9CODX variable and the total score was 
included in the analysis. The significant predictor variables were then included 
in multivariable logistic regression model. RESULTS: Brand users were more 
likely to be White (non-Hispanic) (OR=2.158, 95% CI=1.27-3.659), female 
(OR=1.678, 95% CI=1.109-2.537), having private insurance (OR=1.481, 95% 
CI=1.028-2.134) and from upper middle income class (family’s total income: 
$100,000-$500,000) (OR=1.595, 95% CI=1.030-2.471). However, race (White (non-
Hispanic)) and gender (female) variables were found to be significantly 
associated with brand utilization (P<0.05) after accounting for income and 
insurance coverage. Participants with zero CCI score (absence of CCI’s 17 chronic 
medical conditions) were more likely to be brand user (OR=1.286, 95% CI=0.901-
1.837) although this was not found to be statistically significant (P>0.05). 
CONCLUSIONS: Despite some case reports and bioequivalence studies 
suggesting a disadvantage in efficacy and tolerability of generic medications 
compared with brand-name equivalents, the preponderance of evidence 
suggests that generic antidepressants provide cost savings over brand-name 
medications and equal discontinuation rate. Racial as well as gender differences 
in brand antidepressants preferences were identified, which will possibly help 
clinicians counsel patients with higher likelihood of utilizing off-patent brand-
name antidepressants to help dispel any misconceptions about generic 
antidepressants’ efficacy.  
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OBJECTIVES: The Centers for Medicare and Medicaid Services recently increased 
public access to its Medicare data with the release of Basic Stand Alone (BSA) 
Medicare Claims Public Use Files. This study sought to compare the estimates 
obtained from new BSA claims and public survey data on the number of 
prescriptions per visit associated with Alzheimer's disease (AD) among elderly 
patients in the ambulatory setting. METHODS: Visits of Medicare beneficiaries 
aged 65+ with AD (ICD-9-CM 290, 294, 331, or disease indicator variable) were 
identified in two available data years (2008 and 2010) of BSA claims and two 
national surveys (National Ambulatory Medical Care Survey [NAMCS] and 
outpatient component of National Hospital Ambulatory Medical Care Survey 
[NHAMCS]) of the same years. Descriptive statistics were compared between the 
claims and survey sources on patients’ demographics, co-morbidities, and drug 
use. Numbers of prescriptions per visit were compared between patients with 
and without AD through multivariate regressions (Generalized Linear Model with 
Poisson distribution), controlling for age, sex, and a series of co-morbidities. 
RESULTS: Ambulatory visits by Medicare-covered elderly AD patients were 
identified. As compared to the two surveys, the claims source involves more 
female beneficiaries (64.8% vs. 52.9%) and has higher proportion of patients with 
other chronic conditions in addition to AD (88.2% vs. 67.8%). The top 3 co-
morbidities in the claims source are myocardial ischaemia, heart failure and 
diabetes, while the list is different in surveys as arthritis, diabetes and cancer. 
AD contributes an increased drug use of 2.3 prescriptions per visit in claims and 
1.1 prescriptions in surveys, as predicted by multivariate regressions. 
CONCLUSIONS: This study is an initial exploration comparing the new Medicare 
claims source with national surveys on AD patients’ drug use. Further 
evaluations are needed to inform the use of this new public data source in health 
services research.  
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OBJECTIVES: Considering depression as a major public health problem 
worldwide, the aim of our study was to determine the total utilization and 
pattern of use of antidepressants in Serbia in correlation with Finland. 
METHODS: The data on utilization of antidepressant drugs (ATC group N06) 
during the four-year period (2006-2010) were retrieved by a retrospective, 
observational, population-based study. The ATC/DDD methodology was applied 
and the results were expressed in defined daily doses per 1000 inhabitants per 
day (DID). RESULTS: During the observed period of time, the overall utilization of 
antidepressants showed a modest tendency to increase in both countries (12.2% 
in Finland and 15.93% in Serbia). In 2010, overall utilization of antidepressants in 
Serbia (11,67 DID) appeared to be 6 times lower than in Finland (68.83 DID). 
Throughout the whole studied period, the selective serotonine reuptake 
